
Using Available Evidence and Guidelines for Managing an Evolving AML Treatment Paradigm
Presenter:
Gail J. Roboz MD
Professor of Medicine
Director, Clinical and Translational Leukemia Program
Weill Medical College of Cornell University
New York-Presbyterian Hospital
New York, New York, United States
This brief program will begin with a review of NCCN Guidelines® Recommendations for the treatment of AML in individuals 60 years of age or older. Next, the results of the BRIGHT AML 1003 trial comparing glasdegib + LDAC to LDAC alone, the VIALE-A trial comparing venetoclax + azacitidine vs azacitidine alone, and a comparison of CPX-351 vs standard of care cytarabine + daunorubicin (7 + 3 regimen) for induction and consolidation, will be reviewed. The faculty will discuss FLT3 and IDH inhibitor approvals for AML, IDK differentiation syndrome, and measuring MRD in AML. Finally, results of a trial examining oral azacitidine and a meta-analysis of 5 trials examining gemtuzumab ozogamicin will be reviewed.https://www.clinical-care.org/resource-center-details/using-available-evidence-and-guidelines-for-managing-an-evolving-aml-treatment-paradigm
Follow along with the slideset located here:
https://bit.ly/3lJNHYC
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
More episodes from "Decera Clinical Insights"



Don't miss an episode of “Decera Clinical Insights” and subscribe to it in the GetPodcast app.





